Larimar Therapeutics, Inc. (LRMR) stock
LRMRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.02+0.32 (+11.85%)
Close on Nov 13, 2026Market cap $313.73MP/E –Yield –
Larimar Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Larimar Therapeutics's total assets was $165.30M at Jun 30, 2026. For fiscal 2025 it was $145.84M, down 27.2% from the year before. Over ten years it grew -2.6% a year on average. The highest annual figure on record is $200.23M in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $145.84M | -27.2% |
| FY2024 | Dec 31, 2024 | $200.23M | +108.7% |
| FY2023 | Dec 31, 2023 | $95.94M | -24.1% |
| FY2022 | Dec 31, 2022 | $126.41M | +60.7% |
| FY2021 | Dec 31, 2021 | $78.67M | -24.9% |
| FY2020 | Dec 31, 2020 | $104.69M | +1912.8% |
| FY2019 | Dec 31, 2019 | $5.20M | -95.7% |
| FY2018 | Dec 31, 2018 | $121.76M | +15.4% |
| FY2017 | Dec 31, 2017 | $105.51M | -19.8% |
| FY2016 | Dec 31, 2016 | $131.62M | -30.4% |
| FY2015 | Dec 31, 2015 | $189.11M | +60.9% |
| FY2014 | Dec 31, 2014 | $117.52M | +208.1% |
| FY2013 | Dec 31, 2013 | $38.14M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $165.30M | +10.2% |
| Q1 FY2026 | Mar 31, 2026 | $208.51M | +22.5% |
| Q4 FY2025 | Dec 31, 2025 | $145.84M | -27.2% |
| Q3 FY2025 | Sep 30, 2025 | $187.35M | -14.5% |
| Q2 FY2025 | Jun 30, 2025 | $149.99M | -36.8% |
| Q1 FY2025 | Mar 31, 2025 | $170.18M | -31.4% |
| Q4 FY2024 | Dec 31, 2024 | $200.23M | +108.7% |
| Q3 FY2024 | Sep 30, 2024 | $219.02M | +110.7% |
| Q2 FY2024 | Jun 30, 2024 | $237.16M | +112.3% |
| Q1 FY2024 | Mar 31, 2024 | $248.21M | +108.7% |
| Q4 FY2023 | Dec 31, 2023 | $95.94M | -24.1% |
| Q3 FY2023 | Sep 30, 2023 | $103.95M | -21.8% |
| Q2 FY2023 | Jun 30, 2023 | $111.72M | +77.7% |
| Q1 FY2023 | Mar 31, 2023 | $118.91M | +67.0% |
| Q4 FY2022 | Dec 31, 2022 | $126.41M | +60.7% |
| Q3 FY2022 | Sep 30, 2022 | $133.02M | +51.3% |
| Q2 FY2022 | Jun 30, 2022 | $62.85M | -22.3% |
| Q1 FY2022 | Mar 31, 2022 | $71.22M | -23.4% |
| Q4 FY2021 | Dec 31, 2021 | $78.67M | -24.9% |
| Q3 FY2021 | Sep 30, 2021 | $87.94M | -22.8% |
| Q2 FY2021 | Jun 30, 2021 | $80.93M | -35.5% |
| Q1 FY2021 | Mar 31, 2021 | $93.02M | +26.2% |
| Q4 FY2020 | Dec 31, 2020 | $104.69M | +1912.8% |
| Q3 FY2020 | Sep 30, 2020 | $113.96M | +22.7% |
| Q2 FY2020 | Jun 30, 2020 | $125.46M | +20.8% |
| Q1 FY2020 | Mar 31, 2020 | $73.70M | -33.1% |
| Q4 FY2019 | Dec 31, 2019 | $5.20M | -95.7% |
| Q3 FY2019 | Sep 30, 2019 | $92.89M | -29.6% |
| Q2 FY2019 | Jun 30, 2019 | $103.88M | +30.2% |
| Q1 FY2019 | Mar 31, 2019 | $110.19M | +19.0% |
| Q4 FY2018 | Dec 31, 2018 | $121.76M | +15.4% |
| Q3 FY2018 | Sep 30, 2018 | $131.95M | +37.1% |
| Q2 FY2018 | Jun 30, 2018 | $79.80M | -26.7% |
| Q1 FY2018 | Mar 31, 2018 | $92.61M | -22.4% |
| Q4 FY2017 | Dec 31, 2017 | $105.51M | -19.8% |
| Q3 FY2017 | Sep 30, 2017 | $96.26M | -32.5% |
| Q2 FY2017 | Jun 30, 2017 | $108.85M | – |
| Q1 FY2017 | Mar 31, 2017 | $119.37M | – |
| Q4 FY2016 | Dec 31, 2016 | $131.62M | – |
| Q3 FY2016 | Sep 30, 2016 | $142.71M | – |
See a number that looks wrong?